Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 63

Cited In for PubMed (Select 22571202)

1.

A man with a fracture from minor trauma.

Yang SM, Lo CM.

World J Emerg Med. 2014;5(4):306-9. doi: 10.5847/wjem.j.issn.1920-8642.2014.04.011.

2.

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma.

Al-Mansour Z, Ramanathan M.

Adv Hematol. 2014;2014:652395. doi: 10.1155/2014/652395. Epub 2014 Nov 24. Review.

3.

Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma.

Fall DJ, Stessman H, Patel SS, Sachs Z, Van Ness BG, Baughn LB, Linden MA.

J Cancer. 2014 Sep 21;5(9):720-7. doi: 10.7150/jca.9864. eCollection 2014. Review.

4.

Novel agents and new therapeutic approaches for treatment of multiple myeloma.

Ria R, Reale A, Vacca A.

World J Methodol. 2014 Jun 26;4(2):73-90. doi: 10.5662/wjm.v4.i2.73. eCollection 2014 Jun 26. Review.

5.

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.

Offidani M, Corvatta L, Caraffa P, Gentili S, Maracci L, Leoni P.

Onco Targets Ther. 2014 Sep 29;7:1793-800. doi: 10.2147/OTT.S49187. eCollection 2014. Review.

6.

Therapeutic advancements in multiple myeloma.

Gozzetti A, Candi V, Papini G, Bocchia M.

Front Oncol. 2014 Sep 4;4:241. doi: 10.3389/fonc.2014.00241. eCollection 2014. Review.

7.

Advances in multiple myeloma therapy during two past decades.

Spicka I.

Comput Struct Biotechnol J. 2014 Jun 11;10(16):38-40. doi: 10.1016/j.csbj.2014.05.005. eCollection 2014 Jun. Review.

8.

Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups.

Ailawadhi S, Swaika A, Razavi P, Yang D, Chanan-Khan A.

Blood Cancer J. 2014 Sep 5;4:e243. doi: 10.1038/bcj.2014.63.

9.
10.

Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials.

Gao M, Gao L, Yang G, Tao Y, Tompkins VS, Wu X, Xu H, Zhan F, Shi J.

Int J Clin Exp Pathol. 2014 May 15;7(6):3073-80. eCollection 2014.

11.

Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective.

Desai M, Newberry K, Ou Z, Wang M, Zhang L.

Ther Adv Hematol. 2014 Jun;5(3):91-101. doi: 10.1177/2040620714532124. Review.

12.

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation.

Fouquet G, Hebraud B, Garciaz S, Stoppa AM, Roussel M, Caillot D, Chrétien ML, Arnulf B, Szalat R, Garderet L, Benajiba L, Pegourie B, Regny C, Royer B, Caulier A, Touzeau C, Tessoulin B, Fermand JP, Facon T, Attal M, Loiseau HA, Moreau P, Leleu X.

J Cancer. 2014 Mar 11;5(3):248-52. doi: 10.7150/jca.8541. eCollection 2014.

13.

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.

Martinez-Lopez J, Lahuerta JJ, Pepin F, González M, Barrio S, Ayala R, Puig N, Montalban MA, Paiva B, Weng L, Jiménez C, Sopena M, Moorhead M, Cedena T, Rapado I, Mateos MV, Rosiñol L, Oriol A, Blanchard MJ, Martínez R, Bladé J, San Miguel J, Faham M, García-Sanz R.

Blood. 2014 May 15;123(20):3073-9. doi: 10.1182/blood-2014-01-550020. Epub 2014 Mar 19.

14.

Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers.

Mohty M, Harousseau JL.

Haematologica. 2014 Mar;99(3):408-16. doi: 10.3324/haematol.2013.096149. No abstract available.

15.

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.

Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network.

Haematologica. 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358.

16.

Staging and prognostication of multiple myeloma.

Fonseca R, Monge J, Dimopoulos MA.

Expert Rev Hematol. 2014 Feb;7(1):21-31. doi: 10.1586/17474086.2014.882224. Review.

17.

Trial Watch: Lenalidomide-based immunochemotherapy.

Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Nov 1;2(11):e26494. Epub 2013 Oct 21. Review.

18.

Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.

Hourigan CS, McCarthy P, de Lima M.

Biol Blood Marrow Transplant. 2014 Feb;20(2):154-63. doi: 10.1016/j.bbmt.2013.11.017. Epub 2013 Nov 27. Review.

19.

Current approaches to the initial treatment of symptomatic multiple myeloma.

Jasielec JK, Jakubowiak AJ.

Int J Hematol Oncol. 2013 Feb;2(1). doi: 10.2217/ijh.13.3.

20.

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.

Offidani M, Corvatta L, Maracci L, Liberati AM, Ballanti S, Attolico I, Caraffa P, Alesiani F, Caravita di Toritto T, Gentili S, Tosi P, Brunori M, Derudas D, Ledda A, Gozzetti A, Cellini C, Malerba L, Mele A, Andriani A, Galimberti S, Mondello P, Pulini S, Coppetelli U, Fraticelli P, Olivieri A, Leoni P.

Blood Cancer J. 2013 Nov 22;3:e162. doi: 10.1038/bcj.2013.58.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk